Chung Y S, Ho J J, Kim Y S, Tanaka H, Nakata B, Hiura A, Motoyoshi H, Satake K, Umeyama K
Cancer. 1987 Oct 1;60(7):1636-43. doi: 10.1002/1097-0142(19871001)60:7<1636::aid-cncr2820600736>3.0.co;2-c.
A radioimmunoassay (RIA) test for human pancreatic cancer-associated antigen (Span-1) was developed to evaluate the diagnosis of various gastrointestinal disorders. Serum Span-1 in normal subjects ranged from 5 to 275 U/ml, with a mean of 58.8 U/ml (+/- 58.7, standard deviation). All control subjects had levels of less than 400 U/ml. Study subjects, 93% with pancreatic cancer, 59% with hepatobiliary cancers, 23% with gastric cancers, and 13% with colonic cancers had serum Span-1 levels greater than 400 U/ml. Sensitivities of Span-1, CA 19-9, and Dupan-2 for pancreatic cancer were 94%, 85%, and 38% respectively. Span-1 in patients with Stage I pancreatic cancer showed a 50% positive rating but CA 19-9 and Dupan-2 showed only 0% and 25%. Although a positive rating of these three antibodies increased in advanced cases, Span-1 showed the highest positive rating. Span-1 reacted with colonic cancer tissues with Lewisa-b- phenotype. However, none of these tissues did not react against CA 19-9. From these results, Span-1 has a good predictive value for detecting pancreatic cancer compared with CA 19-9 and Dupan-2.
为评估各种胃肠道疾病的诊断情况，开发了一种用于检测人胰腺癌相关抗原（Span-1）的放射免疫分析（RIA）试验。正常受试者血清Span-1水平在5至275 U/ml之间，平均为58.8 U/ml（±58.7，标准差）。所有对照受试者的水平均低于400 U/ml。研究对象中，93%的胰腺癌患者、59%的肝胆癌患者、23%的胃癌患者和13%的结肠癌患者血清Span-1水平高于400 U/ml。Span-1、CA 19-9和Dupan-2对胰腺癌的敏感性分别为94%、85%和38%。I期胰腺癌患者中Span-1的阳性率为50%，而CA 19-9和Dupan-2仅为0%和25%。尽管在晚期病例中这三种抗体的阳性率均有所增加，但Span-1的阳性率最高。Span-1与具有Lewis a-b-表型的结肠癌组织发生反应。然而，这些组织均未与CA 19-9发生反应。从这些结果来看，与CA 19-9和Dupan-2相比，Span-1在检测胰腺癌方面具有良好的预测价值。
